spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  hemoglobin A1c 

 HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Feb 2020
Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
Biopharmaceuticals Drug Delivery Endocrinology
 HSMN NewsFeed - 19 Feb 2020
Astellas and Seattle Genetics Receive FDA Breakthrough Therapy Designation for PADCEV(TM) (enfortumab vedotin-ejfv) in Combination with Pembrolizumab in First-Line Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Feb 2019
Hygieia Receives 510(k) Clearance from FDA for Phone App That Enhances Company's d-Nav Insulin Guidance Service
Devices Endocrinology FDA
 HSMN NewsFeed - 31 May 2018
Abbott Introduces the Afinion(TM) 2 Analyzer Rapid Test System for Diabetes Management
Diagnostics Endocrinology Product Launch
 HSMN NewsFeed - 18 Sep 2017
ARKRAY launches ADAMS(TM) A1c HA-8180V System for hemoglobin A1c testing
Diagnostics FDA Product Launch
 HSMN NewsFeed - 21 Jun 2017
EnteroMedics Announces vBloc Therapy to be Presented by Keynote Speaker at Major International Obesity Conference
Devices
 HSMN NewsFeed - 31 May 2017
EnteroMedics Announces First vBloc(R) Neurometabolic Therapy Implant at AMITA Health Adventist Medical Center Bolingbrook
Devices Neurology
 HSMN NewsFeed - 23 Feb 2017
First-Ever Device for Fast and Virtually Painless Blood Draw Receives FDA Clearance
Devices FDA
 HSMN NewsFeed - 14 Apr 2014
Abbott Announces FDA Clearance for a New Test to Help Physicians Quickly and Accurately Diagnose Diabetes
Diagnostics Endocrinology FDA
 HSMN NewsFeed - 11 Mar 2014
Lumena Pharmaceuticals Raises $45 Million in Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 9 May 2013
Abbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes
Diagnostics Endocrinology Regulatory
 HSMN NewsFeed - 10 Jul 2012
Abbott Announces New Test for the Management of Patients with Diabetes
Diagnostics Endocrinology Regulatory
 HSMN NewsFeed - 22 Dec 2010
Corcept Therapeutics Announces Positive Phase 3 Study Results for CORLUX for the Treatment of Cushing's Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2009
Pico-Tesla Starts Pilot Study for Type 2 Diabetes with its Proprietary Magnetic (Magneceutical) Therapy
Devices Endocrinology
 HSMN NewsFeed - 24 Mar 2009
Biodel to Submit New Drug Application for VIAject to FDA
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 6 Nov 2008
FDA Approves Ranexa(R) for First Line Anti Anginal Use and Adds New Claims for Reduction of Ventricular Arrhythmias, Bradycardia, New Atrial Fibrillation and HbA1c
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 12 Sep 2008
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 24 Jun 2008
FDA Approves PrandiMet(TM), a Replaglinide and Metformin Fixed-Dose Combination Tablet for Treatment of Type 2 Diabetes
Biopharmaceuticals FDA Endocrinology
 HSMN NewsFeed - 14 Apr 2008
AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults With Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 19 Jan 2008
Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 7 Dec 2007
FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 6 Nov 2007
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Biopharmaceuticals Cardiology Endocrinology
 HSMN NewsFeed - 20 Aug 2007
Elixir Pharmaceuticals Initiates Final Phase III Clinical Study Prior to NDA
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 14 Jun 2007
Living Cell Technologies Announces First Diabetes Patient Successfully Dosed in Phase I/IIa DiabeCell(R) Trial
Regenerative Medicine Endocrinology
 HSMN NewsFeed - 12 Apr 2007
XOMA Announces Clinical Trial Plans for XOMA 052 in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 17 Jan 2007
Elixir Pharmaceuticals Presents New Data Highlighting Ghrelin Inhibition as a Potential Method for Regulating Metabolism and Treating Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 4 Dec 2006
Landmark Study Shows Avandia(R) (rosiglitazone maleate) Is More Effective Than Metformin or a Sulfonylurea in Long-Term Blood Sugar Control in Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Oct 2006
MacroGenics Receives Orphan Drug Designation From FDA for Monoclonal Antibody to Treat Type 1 Diabetes
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 14 Sep 2006
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
Biopharmaceuticals Endocrinology
Return to NewsFeed  

 Additional items found! 28

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 28 additional stories matching:
hemoglobin A1c
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!